Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma

NCT03729245 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT03729245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03729245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Lead sponsor
Nektar Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
December 18, 2018
Completion date
October 19, 2022
Enrollment
623 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma, renal cell carcinoma